RT Journal Article
SR Electronic
T1 Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00411-2021
DO 10.1183/23120541.00411-2021
VO 7
IS 4
A1 Andreas Jung
A1 Annalisa Orenti
A1 Fiona Dunlevy
A1 Elina Aleksejeva
A1 Egil Bakkeheim
A1 Vladimir Bobrovnichy
A1 Siobhán B. Carr
A1 Carla Colombo
A1 Harriet Corvol
A1 Rebecca Cosgriff
A1 Géraldine Daneau
A1 Deniz Dogru
A1 Pavel Drevinek
A1 Andrea Dugac Vukic
A1 Isabelle Fajac
A1 Alice Fox
A1 Stojka Fustik
A1 Vincent Gulmans
A1 Satenik Harutyunyan
A1 Elpis Hatziagorou
A1 Irena Kasmi
A1 Hana Kayserová
A1 Elena Kondratyeva
A1 Uroš Krivec
A1 Halyna Makukh
A1 Kestutis Malakauskas
A1 Edward F. McKone
A1 Meir Mei-Zahav
A1 Isabelle de Monestrol
A1 Hanne Vebert Olesen
A1 Rita Padoan
A1 Tsitsino Parulava
A1 Maria Dolores Pastor-Vivero
A1 Luísa Pereira
A1 Guergana Petrova
A1 Andreas Pfleger
A1 Liviu Pop
A1 Jacqui G. van Rens
A1 Milan Rodic´
A1 Marc Schlesser
A1 Valérie Storms
A1 Oxana Turcu
A1 Lukasz Woz´niacki
A1 Panayiotis Yiallouros
A1 Anna Zolin
A1 Damian G. Downey
A1 Lutz Naehrlich
YR 2021
UL http://openres.ersjournals.com/content/7/4/00411-2021.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.Methods In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.Results Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0–18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7–35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4–17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted versus non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for Pseudomonas aeruginosa infection and poorer lung function).Conclusion SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.In a European study of #SARSCoV2 infection in 828 people with #cysticfibrosis, those with moderate–severe lung disease, CF-related diabetes and lung transplant had poorer outcomes. People with CF, especially these groups, should shield in priority. https://bit.ly/3vPjD2f